A policy change allowing approval of some new drugs based on one adequate and well-controlled study could accelerate ...

The Trump administration’s latest effort to lower drug costs is expanding to biosimilars, medications that are highly similar to biologic drugs made with or isolated from living organisms such as ...

Biosimilars have yet to achieve their main purpose: to reduce the costs of complex biological drugs, as generics do for small molecules. Multiple barriers, from development costs to the contracting ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of medicines ...

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma Early-phase clinical trials (EPCTs) have been ...

Jan 30 (Reuters) - Merck (MRK.N), opens new tab plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in ...